A New Function for Drug Combination Dose Finding Trials

Overview

Journal Sci Rep

Specialty Science

Date 2024 Feb 12

PMID 38346971

Authors

Jiacheng Xiao

Weijia Zhang

Affiliations

Soon will be listed here.

Abstract

Combination drugs play an essential role in treating cancers. The challenging part of the combination drugs are to specify the dose-toxicity ordering, which means the sequences of dose escalation and de-escalation in process of dose findings should be pre-determined. In the paper, we extend a novel function of the continual reassessment method based on the combination of the normal distribution for drug-combination dose-finding trials and systematically evaluate its performance using a template of four performance measures EARS (Efficiency, Accuracy, Reliability, Selection). Dose escalation and deescalation rules are based on the nearest neighborhood continual reassessment method for a combination drug, and we specify all possible dose-toxicity orderings in the trial. Simulation demonstrates that the new design is efficient, accurate and reasonably reliable.

References

Harrington J, Wheeler G, Sweeting M, Mander A, Jodrell D . Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol. 2013; 10(5):277-88. DOI: 10.1038/nrclinonc.2013.35. View

Collins J, Grieshaber C, Chabner B . Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst. 1990; 82(16):1321-6. DOI: 10.1093/jnci/82.16.1321. View

Sweeting M, Mander A . Escalation strategies for combination therapy Phase I trials. Pharm Stat. 2012; 11(3):258-66. PMC: 3573644. DOI: 10.1002/pst.1497. View

Yan F, Mandrekar S, Yuan Y . Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clin Cancer Res. 2017; 23(15):3994-4003. PMC: 5554436. DOI: 10.1158/1078-0432.CCR-17-0220. View

Garrett-Mayer E . The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006; 3(1):57-71. DOI: 10.1191/1740774506cn134oa. View

Wang K, Ivanova A . Two-dimensional dose finding in discrete dose space. Biometrics. 2005; 61(1):217-22. DOI: 10.1111/j.0006-341X.2005.030540.x. View

Riviere M, Dubois F, Zohar S . Competing designs for drug combination in phase I dose-finding clinical trials. Stat Med. 2014; 34(1):1-12. DOI: 10.1002/sim.6094. View

Marchenko O, Fedorov V, Lee J, Nolan C, Pinheiro J . Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges. Ther Innov Regul Sci. 2017; 48(1):20-30. PMC: 5489916. DOI: 10.1177/2168479013513889. View

Masters J, Koberle B . Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003; 3(7):517-25. DOI: 10.1038/nrc1120. View

10.

Kramar A, Lebecq A, Candalh E . Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Stat Med. 1999; 18(14):1849-64. DOI: 10.1002/(sici)1097-0258(19990730)18:14<1849::aid-sim222>3.0.co;2-i. View

11.

Wages N, Ivanova A, Marchenko O . Practical designs for Phase I combination studies in oncology. J Biopharm Stat. 2015; 26(1):150-66. PMC: 4720553. DOI: 10.1080/10543406.2015.1092029. View

12.

Hirakawa A, Wages N, Sato H, Matsui S . A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. Stat Med. 2015; 34(24):3194-213. PMC: 4806394. DOI: 10.1002/sim.6533. View

13.

Lee B, Fan S . A two-dimensional search algorithm for dose-finding trials of two agents. J Biopharm Stat. 2012; 22(4):802-18. DOI: 10.1080/10543406.2012.676587. View

14.

OQuigley J, Pepe M, Fisher L . Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990; 46(1):33-48. View

15.

Wages N, Conaway M . Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharm Stat. 2013; 12(4):217-24. PMC: 3771354. DOI: 10.1002/pst.1575. View

16.

Le Tourneau C, Lee J, Siu L . Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009; 101(10):708-20. PMC: 2684552. DOI: 10.1093/jnci/djp079. View

17.

Paoletti X, Ezzalfani M, Le Tourneau C . Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol. 2015; 26(9):1808-1812. PMC: 4551156. DOI: 10.1093/annonc/mdv266. View

18.

Yuan Y, Yin G . Sequential continual reassessment method for two-dimensional dose finding. Stat Med. 2008; 27(27):5664-78. DOI: 10.1002/sim.3372. View

19.

Iasonos A, Wilton A, Riedel E, Seshan V, Spriggs D . A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials. 2008; 5(5):465-77. PMC: 2637378. DOI: 10.1177/1740774508096474. View

20.

Wages N, Conaway M, OQuigley J . Dose-finding design for multi-drug combinations. Clin Trials. 2011; 8(4):380-9. PMC: 3485079. DOI: 10.1177/1740774511408748. View